Cefaclor

DRUG NAME: Cefaclor

INN / USAN: Cefaclor (no difference between INN and USAN)

ℹ️ Cefaclor is available as the free base in immediate-release capsules and oral suspensions, and as cefaclor monohydrate in modified-release (CD/SR) tablet formulations. The monohydrate form is used specifically for the controlled-delivery matrix and is not dose-interchangeable with the immediate-release capsule on a milligram-for-milligram basis due to different release profiles. Dosing for each formulation type is addressed separately under Indications + Dosing.

---

Therapeutic Class

---

Subclass

---

Speciality

• Primary Speciality: Infectious Disease
• Also used in: ENT, Pulmonology, Paediatrics

---

Schedule (India)

• All formulations of cefaclor (capsules, modified-release tablets, dry syrup for oral suspension) fall under Schedule H.
• Requires a valid prescription for dispensing. No OTC status for any formulation.
• Not classified under Schedule H1 (no additional record-keeping requirement for the pharmacist beyond standard Schedule H prescription retention).

---

Route(s)

ℹ️ Cefaclor is available only as an oral formulation. No parenteral, topical, or inhaled forms exist.

---

Biosimilar Status

---

Formulations Available in India

ℹ️ No commonly prescribed or CDSCO-approved FDCs containing cefaclor are in widespread clinical use in India. Cefaclor is predominantly prescribed as a single-ingredient formulation.

⛔ No FDC of cefaclor has been specifically banned by CDSCO as of the date of this monograph. However, prescribers should verify the CDSCO FDC ban list (updated periodically) before prescribing any combination product.

---

PHARMACOKINETICS

Primary Pharmacokinetic Parameters

Drug Transporter Profile

Prodrug Status

Non-Linear Pharmacokinetics

---

Population PK Notes

---

Key PK-Guided Clinical Notes

---

ADULT INDICATIONS + DOSING

⚠️ Antimicrobial Stewardship Reminder: Cefaclor is a second-generation cephalosporin. Before prescribing, consider whether a narrower-spectrum agent (e.g., amoxicillin) or no antibiotic at all is appropriate. Use culture and sensitivity data when available. Avoid empirical broad-spectrum use where a targeted agent would suffice.

ℹ️ NLEM Status: Cefaclor is NOT included in the current NLEM India (2022 edition). Among oral cephalosporins, cephalexin (1st generation) and cefixime (3rd generation) are included in the NLEM. This does not preclude cefaclor’s use but may affect cost-effectiveness considerations and government supply availability.

ℹ️ Formulation-Specific Dosing Alert: The immediate-release (IR) capsules and the modified-release (CD/SR) tablets have different dosing schedules, bioavailability profiles, and food requirements. They are NOT interchangeable on a milligram-for-milligram basis. Dosing for each is specified separately throughout this section.

---

Antimicrobial Spectrum — Quick Reference

⚠️ Rising resistance note: Indian surveillance data (ICMR AMR surveillance network) shows increasing resistance among common uropathogens (E. coli, Klebsiella) to second-generation cephalosporins. Always consider local antibiogram data when treating UTIs empirically.

---

Primary Indications (Approved / Standard in India) — Adults

---

1. Upper Respiratory Tract Infections (URTI) — Acute Bacterial Pharyngitis / Tonsillitis, Acute Bacterial Sinusitis, Acute Otitis Media

ℹ️ These three conditions are grouped because cefaclor dosing is broadly similar across them. Condition-specific notes are provided separately below the dosing table.

• Duration: 10 days (to ensure Group A Streptococcal eradication and prevent rheumatic fever — this is non-negotiable; shorter courses are inadequate for GAS pharyngitis)
• When to prefer cefaclor: Consider in patients with penicillin allergy (non-anaphylactic type — delayed rash, GI intolerance to amoxicillin) where oral cephalosporins are deemed safe. Also reasonable when H. influenzae co-infection is suspected (e.g., concurrent sinusitis).
• When NOT to use: ⛔ Do not use in patients with history of immediate/anaphylactic-type penicillin allergy (urticaria, angioedema, bronchospasm, anaphylaxis) — cross-reactivity risk with cephalosporins is ~1–2%, and in this scenario, prefer azithromycin or clindamycin instead. Also, do not use for viral pharyngitis — confirm bacterial aetiology via clinical criteria (Centor/McIsaac score ≥3) or rapid antigen test/culture.
• Preferred alternatives in India: Amoxicillin (500 mg TDS × 10 days) is the first-line drug for GAS pharyngitis (API Textbook of Medicine, ICMR guidelines). Cefaclor is a second-line option. Phenoxymethylpenicillin (Penicillin V) remains effective but is less commonly available/used in India.
• NLEM status for this indication: Not applicable — cefaclor is not in NLEM. Amoxicillin (the preferred drug) is in NLEM.
• Time to expected clinical response: Fever and throat pain typically improve within 48–72 hours. Failure to improve by 72 hours warrants reassessment.
• Treatment failure criteria: Persistent fever, worsening symptoms, or recurrence within 2 weeks → consider culture, assess compliance, switch to amoxicillin-clavulanate or azithromycin.
• Mandatory baseline investigations: None mandatory for uncomplicated pharyngitis. Throat culture or rapid antigen detection test (RADT) is recommended if available — especially in children and young adults at risk of rheumatic fever (still highly prevalent in India).
• Specialist initiation: Not required. Appropriate for primary care / PHC prescribing.
• Indian guideline source: API Textbook of Medicine (relevant chapter on Streptococcal infections); ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes (2019 edition).
• Key safety warning: ⚠️ In India, rheumatic fever and rheumatic heart disease remain significant. Incomplete treatment of GAS pharyngitis is a major risk factor. Always emphasise full 10-day course completion.
• Dose adjustment scenarios: Renal impairment — see Renal Adjustment section.

• Duration: 10–14 days (standard); 5–7 days may be considered for mild cases with clear clinical response.
• When to prefer cefaclor: Second-line option when amoxicillin or amoxicillin-clavulanate is not tolerated. Cefaclor provides coverage against H. influenzae and M. catarrhalis — the two most common beta-lactamase-producing sinusitis pathogens.
• When NOT to use: Chronic sinusitis (often polymicrobial including anaerobes — cefaclor has poor anaerobic coverage); complicated sinusitis (orbital/intracranial extension); suspected fungal sinusitis.
• Preferred alternatives in India: Amoxicillin-clavulanate (first-line for ABRS per Indian ENT practice and API Textbook). For penicillin-allergic patients: cefaclor or cefuroxime (oral) are reasonable options.
• Time to expected clinical response: 48–72 hours. If no improvement by day 3, reassess diagnosis and consider imaging (CT sinuses) and switch to amoxicillin-clavulanate or doxycycline + metronidazole.
• Treatment failure criteria: Persistent symptoms beyond 72 hours, worsening facial pain/fever, or development of complications → switch antibiotic and consider ENT referral.
• Mandatory baseline investigations: None mandatory. CT sinuses is recommended if chronic or complicated disease is suspected — not for uncomplicated acute sinusitis.
• Specialist initiation: Not required for acute uncomplicated sinusitis. ENT referral recommended for chronic, recurrent, or complicated sinusitis.

• Duration: 7–10 days (standard for adults; 5–7 days may be adequate for mild cases in otherwise healthy adults).
• When to prefer cefaclor: When amoxicillin has failed or is not tolerated. Provides better coverage of beta-lactamase-producing H. influenzae than amoxicillin alone.
• When NOT to use: Complicated AOM (mastoiditis, intracranial complications); chronic suppurative otitis media (CSOM) — requires different antibiotic approach and often topical ear drops ± systemic antibiotics with anti-pseudomonal or anaerobic coverage.
• Preferred alternatives in India: Amoxicillin (first-line); amoxicillin-clavulanate (first-line if beta-lactamase-producing organism suspected); cefuroxime axetil (alternative oral cephalosporin).
• Time to expected clinical response: 48–72 hours.
• Specialist initiation: Not required for uncomplicated AOM. ENT referral for recurrent AOM (≥3 episodes in 6 months), treatment failure, or complications.

---

2. Lower Respiratory Tract Infections (LRTI) — Acute Bronchitis, Acute Exacerbation of Chronic Bronchitis (AECB), Mild Community-Acquired Pneumonia (CAP)

• ⚠️ Most cases of acute bronchitis are viral and DO NOT require antibiotics. Antibiotics are recommended ONLY when bacterial superinfection is suspected (purulent sputum >7–10 days, high fever, declining clinical trajectory, patient with underlying COPD/immunosuppression).
• Duration: 5–7 days (if antibiotics are indicated).
• Preferred alternatives in India: Amoxicillin or doxycycline are commonly used first-line. Cefaclor is a second-line option.
• Time to expected clinical response: 48–72 hours. Cough may persist for 2–3 weeks even after successful bacterial clearance.
• NLEM status: Not applicable.
• Specialist initiation: Not required. Appropriate for primary care.

• Duration: 5–7 days.
• When to prefer cefaclor: When an oral cephalosporin is desired and amoxicillin-clavulanate is not tolerated. Provides coverage against H. influenzae and M. catarrhalis — key AECB pathogens.
• When NOT to use: Severe AECOPD requiring hospitalisation (parenteral antibiotics preferred — ceftriaxone, piperacillin-tazobactam); suspected Pseudomonas colonisation (common in severe COPD with frequent exacerbations and bronchiectasis) — cefaclor has no Pseudomonas coverage.
• Preferred alternatives in India: Amoxicillin-clavulanate (first-line per Indian Chest Society / GOLD guidelines adapted for India); doxycycline; azithromycin.
• Anthonisen criteria for antibiotic use in AECB: Antibiotics are recommended when ≥2 of: increased dyspnoea, increased sputum volume, increased sputum purulence. If only 1 criterion present, antibiotics are generally not needed.
• Indian guideline source: Indian Chest Society guidelines for COPD management; API Textbook of Medicine (chapter on COPD).
• Time to expected clinical response: 48–72 hours.
• Treatment failure criteria: Worsening dyspnoea, persistent purulent sputum, fever — reassess, obtain sputum culture, and consider switching to amoxicillin-clavulanate or a fluoroquinolone (levofloxacin/moxifloxacin) or parenteral antibiotics.
• Specialist initiation: Not required for outpatient AECB. Pulmonology referral for frequent exacerbators (≥2 per year).

• ⚠️ Cefaclor has significant limitations for CAP: It does NOT cover atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila), which account for a significant proportion of CAP in younger adults. Therefore, cefaclor as monotherapy is suboptimal for CAP in most clinical scenarios.
• Duration: 5–7 days (minimum 5 days; patient should be afebrile for ≥48 hours before stopping).
• When to prefer cefaclor: Very limited role. May be considered ONLY for mild CAP in elderly patients where S. pneumoniae or H. influenzae is the most likely pathogen and atypical coverage is not a priority (e.g., CURB-65 score 0–1, no atypical features). Even here, amoxicillin ± macrolide is preferred.
• When NOT to use: Moderate-to-severe CAP (CURB-65 ≥2); suspected atypical pneumonia (age <40, non-productive cough, extrapulmonary features); aspiration pneumonia (anaerobic coverage needed); hospital-acquired pneumonia.
• Preferred alternatives in India:
• • ICMR/Indian guidelines: Amoxicillin ± azithromycin (for outpatient mild CAP) OR amoxicillin-clavulanate + azithromycin/doxycycline.
  • Respiratory fluoroquinolones (levofloxacin, moxifloxacin) — for penicillin-allergic patients or treatment failure, but fluoroquinolone stewardship is encouraged.
• Mandatory baseline investigations: Chest X-ray (recommended). Sputum Gram stain and culture if available. SpO₂ assessment.
• Treatment failure criteria: No improvement or worsening within 48–72 hours → obtain chest X-ray, sputum culture, blood cultures; consider hospitalisation and parenteral antibiotics.
• Indian guideline source: ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes (2019); Indian Chest Society/NCCP CAP guidelines.
• Specialist initiation: Not required for mild outpatient CAP. Pulmonology/Infectious Disease referral for treatment failure or complicated pneumonia.

---

3. Uncomplicated Urinary Tract Infections (UTI) — Acute Cystitis

• When to prefer cefaclor: Very limited first-line role in current Indian practice given rising cephalosporin resistance among uropathogens. Consider ONLY when culture shows susceptibility and first-line agents are not tolerable.
• When NOT to use: ⛔ Complicated UTI, pyelonephritis (except very mild, confirmed susceptible — and even then, first-generation cephalosporins or amoxicillin-clavulanate are preferred), catheter-associated UTI, UTI in men (usually complicated by definition).
• ⚠️ Indian resistance context: ICMR AMR surveillance data consistently shows high rates of E. coli resistance to cephalosporins in Indian community isolates (often >40–60% in some regions due to ESBL production). Cefaclor should NOT be used empirically for UTI in India without culture-sensitivity data unless local antibiogram supports it.
• Preferred alternatives in India for uncomplicated cystitis:
• • First-line: Nitrofurantoin 100 mg BD × 5 days (ICMR-recommended; best resistance profile)
  • Alternative: Fosfomycin 3 g single dose (oral)
  • Avoid fluoroquinolones for uncomplicated cystitis (stewardship concern)
• NLEM status: Not applicable.
• Mandatory baseline investigations: Urine routine and microscopy (recommended). Urine culture and sensitivity (recommended in India given high resistance rates; mandatory in recurrent UTI, treatment failure, or complicated UTI).
• Time to expected clinical response: Symptom improvement within 24–48 hours. Dysuria should resolve by day 3.
• Treatment failure criteria: Persistent or worsening symptoms at 48–72 hours → obtain urine culture if not already sent; switch antibiotic based on sensitivity.
• Specialist initiation: Not required. Appropriate for primary care. Urology/Nephrology referral for recurrent UTI (≥3 per year), complicated UTI, or structural abnormalities.
• Indian guideline source: ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes (2019); API Textbook of Medicine (chapter on UTI).
• Key safety warning: ⚠️ Avoid using cefaclor empirically for UTI in India unless local antibiogram supports susceptibility. Empirical cephalosporin use contributes to ESBL selection pressure.

---

4. Skin and Soft Tissue Infections (SSTIs) — Uncomplicated

• When to prefer cefaclor: Uncomplicated skin infections (impetigo, cellulitis, wound infections) caused by susceptible S. aureus (MSSA) or Streptococcus pyogenes. Reasonable option when amoxicillin-clavulanate is not tolerated.
• When NOT to use: ⛔ Suspected or confirmed MRSA infection (cefaclor has NO MRSA activity — prevalence of community-acquired MRSA in India varies by region but is significant in many urban centres). ⛔ Deep-seated infections (necrotising fasciitis, osteomyelitis, septic arthritis). ⛔ Animal/human bite wounds (require anaerobic coverage — amoxicillin-clavulanate preferred). ⛔ Diabetic foot infections (usually polymicrobial including anaerobes and Gram-negatives resistant to cefaclor).
• Preferred alternatives in India:
• • MSSA skin infections: Cephalexin (first-generation — narrower spectrum, preferred per antimicrobial stewardship), cloxacillin/dicloxacillin, amoxicillin-clavulanate.
  • Suspected MRSA: Cotrimoxazole, doxycycline, clindamycin, linezolid (based on severity).
• NLEM status: Not applicable.
• Time to expected clinical response: Erythema and swelling should begin improving within 48–72 hours. Mark the borders of cellulitis to track progression/regression.
• Treatment failure criteria: Expanding erythema, persistent fever, development of fluctuance or crepitus at 48–72 hours → reassess; consider incision and drainage if abscess; switch antibiotic (add MRSA coverage); obtain wound culture.
• Mandatory baseline investigations: None mandatory for uncomplicated SSTI. Wound culture (recommended if abscess present, recurrent infection, or treatment failure). Blood cultures if systemic toxicity present (but such patients usually need parenteral antibiotics, not cefaclor).
• Specialist initiation: Not required for uncomplicated SSTI. Surgical referral for abscess drainage. Infectious Disease referral for deep-seated or non-resolving infections.
• Indian guideline source: API Textbook of Medicine; IADVL (Indian Association of Dermatologists, Venereologists and Leprologists) guidelines for bacterial skin infections.
• Key safety warning: ⚠️ India has a high prevalence of community-acquired MRSA (CA-MRSA). Do not assume S. aureus SSTI will respond to cephalosporins without culture confirmation in areas of high MRSA prevalence.

---

Secondary Indications — Adults Only (Off-Label)

• Status: OFF-LABEL
• Dose: 250 mg once at bedtime (continuous low-dose prophylaxis) for 6–12 months
• Maximum dose: Max 250 mg per dose; Max 250 mg per day (prophylactic dosing)
• Duration: 6–12 months, then reassess need
• Specialist only: Recommended — Urology or Gynaecology oversight preferred
• Evidence basis: Limited. Small observational studies and expert consensus support low-dose cephalosporin prophylaxis for recurrent UTI. Not based on large RCTs specific to cefaclor.
• Level of evidence quality:Weak — Case series, expert opinion, and extrapolation from other cephalosporins.
• Preferred alternatives: Nitrofurantoin 50–100 mg at bedtime (preferred first-line for UTI prophylaxis in India per ICMR guidelines — superior evidence and resistance profile); cotrimoxazole 240 mg at bedtime (alternative).
• Clinical note: ⚠️ Long-term cephalosporin use for UTI prophylaxis is not recommended as a routine practice in India due to antimicrobial resistance concerns (ESBL selection pressure). Reserve for patients in whom nitrofurantoin and cotrimoxazole are contraindicated or not tolerated. Periodic urine culture (every 3–6 months) recommended during prophylaxis.

• Status: OFF-LABEL but accepted standard practice in India (antibiotic step-down / IV-to-oral switch therapy)
• Dose: 500 mg TDS (IR capsule)
• Maximum dose: Max 500 mg per dose; Max 1500 mg per day
• Duration: To complete total antibiotic course (usually 7–14 days total including parenteral phase)
• Specialist only: Should be guided by the treating physician managing the infection
• Evidence basis: Principle of IV-to-oral step-down therapy is well established. Cefaclor is one option when the isolate is confirmed susceptible and the patient is clinically improving, tolerating oral intake, and afebrile for ≥24–48 hours. However, more commonly used oral step-down agents include amoxicillin-clavulanate, cefixime, or cefpodoxime.
• Level of evidence quality:Moderate — Well-established clinical principle; specific data for cefaclor in this role is limited compared to cefixime/cefpodoxime.
• Clinical note: Always confirm sensitivity to cefaclor before switching. Ensure organism is susceptible and not an ESBL producer (ESBLs are resistant to all standard cephalosporins including cefaclor).

ℹ️ No other well-documented secondary (off-label) adult indications for cefaclor were identified with sufficient evidence to include in this formulary.

---

MISSED DOSE / DELAYED DOSE GUIDANCE

Immediate-Release Capsules / Oral Suspension (Three Times Daily — TDS Dosing)

Modified-Release (CD/SR) Tablets (Twice Daily — BD Dosing)

PRN Use

• Not applicable — cefaclor is not a PRN medication.

Prolonged Non-Adherence / Drug Holiday Guidance

• If ≥2 consecutive doses are missed: The antibiotic course may become subtherapeutic, increasing the risk of treatment failure and resistance development. Contact the prescriber to assess whether:
• • The remaining course should be extended by the number of missed days
  • A switch to an alternative antibiotic is warranted (especially if symptoms have worsened)
• No re-titration is needed: Cefaclor can be resumed at the same dose without dose escalation.
• No rebound effect: Cefaclor carries no risk of rebound or withdrawal effects upon sudden discontinuation or resumption.
• ⚠️ Key message to patients: Completing the full antibiotic course is essential. Do not stop early even if symptoms improve.

---

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

ℹ️ Cefaclor is an oral-only drug. No parenteral formulation exists. This section addresses reconstitution of the dry syrup for oral suspension and administration notes for all oral forms.

Reconstitution of Dry Syrup for Oral Suspension

Oral Administration Notes

Cold-Chain Drug Guidance

• Before reconstitution: Store dry powder at room temperature (below 30°C), protected from moisture. No cold-chain required for the dry powder.
• After reconstitution: Refrigeration (2–8°C) recommended. See stability table above.
• ℹ️ In hot Indian climates (>35°C), if refrigeration is unavailable, reconstituted suspension should be used within 7 days. Counsel caregiver to store in the coolest part of the home (e.g., earthen pot, shaded area).

Other Sections (Not Applicable for Oral-Only Drug)

---

PAEDIATRIC DOSING (Specialist Only)

⚠️ Antimicrobial Stewardship Reminder: All paediatric antibiotic prescriptions should follow antimicrobial stewardship principles. Confirm bacterial aetiology before initiating antibiotics where feasible. Viral infections remain the predominant cause of respiratory illness in children.

ℹ️ NLEM / WHO EML Status: Cefaclor is NOT included in the current NLEM India (2022) or WHO EML for Children. Among oral cephalosporins for paediatric use, cephalexin (1st generation) and cefixime (3rd generation) are more commonly recommended in Indian guidelines. Cefaclor remains a valid second-line option when these agents are not tolerated or when susceptibility data supports its use.

---

General Notes

• Monitor for GI tolerance — diarrhoea is the most common adverse effect in children and can lead to dehydration in young infants. Advise caregivers on oral rehydration if loose stools develop.
• Monitor for allergic reactions — urticaria, maculopapular rash, pruritus, angioedema. Report immediately if any rash develops.
• Monitor for superinfection — oral candidiasis (thrush), vulvovaginal candidiasis in older girls — particularly with courses >7 days. Treat with topical antifungals if it develops.
• ⚠️ Serum sickness-like reaction (SSLR): Cefaclor has a uniquely higher incidence of SSLR in children compared to other cephalosporins (~0.02–0.5% per course, higher with repeated courses — up to 0.5–2% with second or subsequent courses in some paediatric series). Characterised by erythema multiforme–like or urticarial rash, arthralgia/arthritis, and fever, typically occurring 7–21 days after starting therapy. This is NOT a true IgE-mediated allergy but a hypersensitivity reaction likely related to reactive cefaclor metabolite (delta-3 intermediate) formation. See dedicated SSLR management box below.
• For prolonged courses (>14 days — uncommon for cefaclor): consider periodic CBC and renal function.
• No routine blood monitoring required for standard short courses (≤14 days) in children with normal baseline organ function.

---

⚠️ Serum Sickness-Like Reaction (SSLR) — Paediatric-Specific Warning & Management

---

Minimum Age and Weight Limits

---

Formulation Suitability for Children

---

• Cefaclor oral suspension has a fruity/strawberry flavour (varies by manufacturer) and is generally well-accepted by children.
• If the child refuses the suspension, it may be mixed with a small amount of cold milk, formula, fruit juice, or soft food immediately before administration — administer within 5 minutes of mixing; do not store the mixture.
• ⚠️ Do not mix with hot liquids (may degrade the drug).
• Bitter aftertaste may occur with some generic brands — switching brands may improve acceptance if the child consistently refuses.

---

Age-Specific Pharmacokinetic Differences

---

• ≥12 years AND ≥40 kg: Use adult dosing schedules (IR capsules 250–500 mg TDS, or CD/SR tablets at adult doses if able to swallow tablets whole with food) — see Part 2.
• 12–15 years but <40 kg: Continue weight-based paediatric dosing up to the adult maximum per dose.
• CD/SR formulation: May be used in adolescents ≥12 years who can swallow tablets whole with food.

---

Neonatal Dosing

⚠️ Neonatal use — NICU supervision only

---

Primary Indications — Paediatric (Approved / Standard in India)

---

1. Upper Respiratory Tract Infections (URTI) — Acute Otitis Media (AOM), Acute Bacterial Pharyngitis / Tonsillitis (GAS), Acute Bacterial Sinusitis

---

• Duration:10 days for children <2 years or with severe symptoms. 7 days may be adequate for children ≥2 years with mild–moderate, unilateral AOM and reliable follow-up.
• When to prefer cefaclor: Second-line oral cephalosporin option when amoxicillin (first-line per IAP guidelines: 80–90 mg/kg/day divided BD or TDS × 10 days) has failed after 48–72 hours, or in children with non-anaphylactic penicillin allergy. Cefaclor provides better beta-lactamase stability against H. influenzae and M. catarrhalis than amoxicillin alone.
• When NOT to use:
• • ⛔ Children with history of immediate/anaphylactic reaction to any penicillin or cephalosporin (urticaria, angioedema, bronchospasm, anaphylaxis)
  • ⛔ Complicated AOM (mastoiditis, facial nerve palsy, intracranial complications) — requires hospitalisation and parenteral antibiotics
  • ⛔ AOM with tympanic membrane perforation and active discharge persisting >6 weeks (chronic suppurative otitis media / CSOM — different management; requires topical + systemic approach, often with anti-pseudomonal/anaerobic coverage)
  • ⛔ Otitis media with effusion (OME) — this is NOT a bacterial infection and does not warrant antibiotics
• Watchful waiting option: IAP guidelines (aligned with AAP 2013/updated) support 48–72 hours of observation (analgesics only, no antibiotics) in children ≥6 months with unilateral, non-severe AOM — with a safety-net antibiotic prescription (caregiver is given a prescription to fill only if symptoms worsen or do not improve). This reduces unnecessary antibiotic use and is underutilised in Indian practice.
• Preferred alternatives in India:
• • First-line: High-dose amoxicillin 80–90 mg/kg/day divided BD or TDS × 10 days (IAP, ICMR)
  • Second-line (amoxicillin failure): Amoxicillin-clavulanate 80–90 mg/kg/day (amoxicillin component) divided BD × 10 days
  • Penicillin-allergic (non-anaphylactic): Cefaclor 40 mg/kg/day TDS, OR cefuroxime axetil 30 mg/kg/day BD
  • Penicillin-allergic (anaphylactic type): Azithromycin 10 mg/kg Day 1, then 5 mg/kg Days 2–5
• NLEM status for this indication: Cefaclor is not in NLEM. Amoxicillin is the NLEM-listed antibiotic for paediatric AOM.
• Time to expected clinical response: Ear pain and fever should improve within 48–72 hours.
• Treatment failure criteria: Persistent fever, worsening ear pain, or new symptoms at 48–72 hours:
• 1. If initially on standard dose (20 mg/kg/day) → escalate to higher dose (40 mg/kg/day)
  2. If already on higher dose or initially on cefaclor as second-line → switch to amoxicillin-clavulanate
  3. For severe/refractory cases → consider tympanocentesis for culture or ceftriaxone IM (single dose 50 mg/kg, max 1 g)
  4. New post-auricular swelling suggesting mastoiditis → urgent ENT referral + hospitalisation + parenteral antibiotics
• Mandatory baseline investigations: Otoscopic examination (mandatory). Tympanometry (recommended if available). No blood tests required for uncomplicated AOM.
• Specialist initiation: Not required — appropriate for primary care / paediatrician prescribing. ENT referral for: recurrent AOM (≥3 episodes in 6 months or ≥4 in 12 months), complications, hearing concerns, consideration for tympanostomy tubes.
• Indian guideline source: IAP Guidelines for Management of AOM; ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes (2019); API Textbook of Medicine.
• Key safety warning: ⚠️ SSLR risk — higher with cefaclor than other cephalosporins, especially during second or subsequent courses. Counsel caregivers (see SSLR box above).

---

• Duration: ⚠️ 10 days — non-negotiable. Shorter courses are inadequate for GAS eradication and fail to prevent rheumatic fever. This is critically important in the Indian context where rheumatic heart disease remains a major cause of cardiovascular morbidity in children and young adults. India has the world’s highest burden of rheumatic heart disease.
• When to prefer cefaclor: Non-anaphylactic penicillin allergy; amoxicillin intolerance (GI); recurrent GAS pharyngitis where carrier state with co-pathogen (beta-lactamase-producing H. influenzae) may be contributing to amoxicillin failure. Some meta-analyses suggest second-generation cephalosporins achieve marginally higher bacteriological cure rates than penicillin V for GAS pharyngitis, but this does not change first-line recommendations.
• When NOT to use:
• • ⛔ Anaphylactic penicillin or cephalosporin allergy — use azithromycin or clindamycin
  • ⛔ Viral pharyngitis — the most common cause of sore throat in children. Confirm bacterial aetiology before prescribing (modified McIsaac score ≥3, RADT, or throat culture). Do not prescribe antibiotics for clinical score <3 without microbiological confirmation.
  • ⛔ Peritonsillar abscess — requires drainage + parenteral antibiotics
• Compliance strategy for India: ⚠️ If compliance with a 10-day oral course is doubtful (very common in Indian primary care/PHC settings — symptom resolution at day 3–4 leads to premature discontinuation), single-dose IM benzathine penicillin G is the preferred strategy:
• • <27 kg: 6 lakh (600,000) units IM × 1 dose
  • ≥27 kg: 12 lakh (1,200,000) units IM × 1 dose
  • This provides reliable GAS eradication with a single visit and is the most effective strategy for rheumatic fever prevention in resource-limited settings (IAP/ICMR recommendation).
• Preferred alternatives in India:
• • First-line: Amoxicillin 50 mg/kg/day (max 1 g/day) divided BD or TDS × 10 days (IAP first-line oral)
  • Alternative first-line: Penicillin V 250 mg BD–TDS × 10 days (limited availability in India)
  • Compliance concerns: IM benzathine penicillin G single dose (see above)
  • Penicillin-allergic (non-anaphylactic): Cephalexin 25–50 mg/kg/day divided BD × 10 days OR cefaclor 20 mg/kg/day TDS × 10 days
  • Penicillin-allergic (anaphylactic type): Azithromycin 12 mg/kg/day × 5 days (max 500 mg/day) OR clindamycin 20 mg/kg/day divided TDS × 10 days (max 1.8 g/day)
• NLEM status: Amoxicillin and benzathine penicillin G are NLEM-listed. Cefaclor is not.
• Time to expected clinical response: Fever and severe throat pain improve within 24–48 hours. Child is considered non-infectious after 24 hours of effective therapy → can return to school.
• Treatment failure criteria: Persistent fever and symptoms at 72 hours, or clinical relapse within 2 weeks → obtain throat culture, assess compliance, consider amoxicillin-clavulanate or clindamycin; exclude peritonsillar abscess.
• Mandatory baseline investigations: Throat examination (mandatory). RADT or throat culture (recommended — particularly important in children aged 3–15 years who are at highest risk for rheumatic fever). ℹ️ ASO titre is NOT useful for acute diagnosis — it reflects past streptococcal infection, not current pharyngitis. Do not order ASO to diagnose acute GAS pharyngitis.
• Specialist initiation: Not required. Appropriate for primary care / paediatrician prescribing.
• Indian guideline source: IAP Guidelines; ICMR Treatment Guidelines for Antimicrobial Use (2019); Indian Academy of Pediatrics Revised Guidelines for Rheumatic Fever (2008, updated practice).

---

• Duration:10–14 days (standard). Some guidelines suggest treating for 7 days beyond symptom resolution.
• Diagnosis in children — when to prescribe antibiotics: Bacterial sinusitis should be diagnosed when upper respiratory symptoms (nasal discharge, cough) persist for ≥10 days without improvement, or when there is severe onset (high fever ≥39°C with purulent nasal discharge for ≥3 consecutive days), or worsening after initial improvement (”double worsening“). ⚠️ Do NOT prescribe antibiotics for simple viral URI — the vast majority of ”sinusitis“ in children is viral and self-limiting.
• When to prefer cefaclor: Second-line when amoxicillin or amoxicillin-clavulanate is not tolerated. Covers beta-lactamase-producing H. influenzae and M. catarrhalis — key sinusitis pathogens.
• When NOT to use:
• • ⛔ Chronic sinusitis (>12 weeks) — often polymicrobial including anaerobes; requires broader-spectrum and longer-duration therapy, often ENT involvement
  • ⛔ Complicated sinusitis (orbital cellulitis, subperiosteal/orbital abscess, intracranial extension) — urgent hospitalisation + parenteral antibiotics + imaging + ENT/ophthalmology
  • ⛔ Suspected fungal sinusitis (immunocompromised children)
• Preferred alternatives in India: Amoxicillin-clavulanate (first-line — IAP, API); amoxicillin alone (for mild cases in low-resistance settings).
• Time to expected clinical response: 48–72 hours. If no improvement by day 3, reassess diagnosis, consider imaging (CT sinuses), and switch to amoxicillin-clavulanate or refer to ENT.
• Specialist initiation: Not required for uncomplicated ABRS. ENT referral for chronic, recurrent, or complicated sinusitis; nasal polyposis; suspected fungal sinusitis.
• Indian guideline source: IAP Guidelines; API Textbook of Medicine; ENT specialist consensus in India.

---

2. Lower Respiratory Tract Infections — Paediatric (Mild CAP, Acute Bronchitis with Bacterial Superinfection)

• ⚠️ Most cases of acute bronchitis in children are viral and DO NOT require antibiotics. Antibiotics are recommended ONLY when bacterial superinfection is suspected (purulent sputum >7–10 days, high-grade fever, worsening trajectory, child with underlying chronic lung disease or immunosuppression).
• Duration: 5–7 days (if antibiotics indicated).
• Preferred alternatives in India: Amoxicillin or amoxicillin-clavulanate (first-line). Cefaclor is second-line.
• Time to expected clinical response: 48–72 hours for fever. Cough may persist for 2–3 weeks even after successful bacterial clearance — counsel caregivers that persistent cough does not necessarily mean treatment failure.

• When to prefer cefaclor: Very limited first-line role. May be considered only when culture/sensitivity confirms a cefaclor-susceptible typical pathogen (S. pneumoniae, H. influenzae) and atypical coverage is not needed.
• When NOT to use:
• • ⛔ Severe pneumonia (WHO classification: chest indrawing, danger signs — inability to drink, lethargy, convulsions, stridor) — requires hospitalisation and parenteral antibiotics
  • ⛔ Suspected atypical pneumonia — Mycoplasma pneumoniae is the most common CAP pathogen in school-age children (5–15 years) in India. Cefaclor has zero activity against Mycoplasma, Chlamydophila, or Legionella. If atypical pneumonia is suspected (school-age child, subacute onset, non-productive cough, wheeze, extrapulmonary features), a macrolide (azithromycin 10 mg/kg day 1, then 5 mg/kg days 2–5) is required.
  • ⛔ Neonatal pneumonia (<2 months — always requires hospitalisation and parenteral antibiotics)
  • ⛔ Suspected Staphylococcal pneumonia (e.g., post-measles, post-influenza pneumonia with pneumatocoeles) — cefaclor’s anti-staphylococcal activity is inferior to first-generation cephalosporins and anti-staphylococcal penicillins
  • ⛔ Aspiration pneumonia (anaerobic coverage needed — amoxicillin-clavulanate or clindamycin)
  • ⛔ Complicated pneumonia (empyema, necrotising pneumonia, lung abscess)
• Preferred alternatives in India (IAP/ICMR guidelines):
• • <5 years (typical pathogen focus): Amoxicillin 80–90 mg/kg/day divided BD × 5 days (IAP/WHO first-line for non-severe CAP). Amoxicillin-clavulanate if beta-lactamase concern.
  • ≥5 years (atypical pathogen likelihood increases): Amoxicillin + azithromycin combination, or azithromycin alone if atypical presentation dominant.
  • Penicillin allergy (non-anaphylactic): Cefaclor or cefuroxime axetil.
  • Cefaclor monotherapy is not recommended as empirical first-line for paediatric CAP.
• NLEM status: Amoxicillin is the NLEM-listed first-line oral antibiotic for paediatric CAP.
• Duration: Minimum 5 days; patient should be afebrile ≥48 hours before stopping. 7–10 days for moderate infection.
• Mandatory baseline investigations: Respiratory rate count (mandatory — WHO/IMNCI criteria for pneumonia diagnosis in children). SpO₂ by pulse oximetry (recommended — if <92% at sea level, hospitalise). Chest X-ray (recommended for suspected pneumonia but not mandatory for outpatient non-severe CAP per WHO/IAP).
• Time to expected clinical response: Fever should improve within 48–72 hours. Cough may persist for 1–2 weeks.
• Treatment failure criteria: Persistent high fever at 48–72 hours, worsening tachypnoea, new danger signs → hospitalise, obtain blood culture, chest X-ray, switch to parenteral antibiotics.
• Specialist initiation: Not required for non-severe outpatient CAP. Paediatric/Pulmonology referral for severe, complicated, or recurrent pneumonia.
• Indian guideline source: IAP Guidelines for Management of CAP in Children; ICMR Treatment Guidelines (2019); WHO Pocket Book of Hospital Care for Children (supportive reference).
• Key safety warning: ⚠️ Cefaclor monotherapy for paediatric CAP risks treatment failure when atypical organisms are the cause. In school-age children (5–15 years), always consider adding or substituting a macrolide.

---

3. Urinary Tract Infections — Paediatric (Uncomplicated Lower UTI / Acute Cystitis)

• ⚠️ All paediatric UTIs (especially first episode) must have urine culture and sensitivity — empirical therapy should be guided by local antibiogram and modified once culture results are available (IAP guideline). This is mandatory, not optional.
• When to prefer cefaclor: ONLY when culture confirms susceptibility and first-line agents (amoxicillin-clavulanate, cephalexin, nitrofurantoin) are not tolerated or available.
• When NOT to use:
• • ⛔ Febrile UTI / suspected pyelonephritis in children (especially <2 years): Any child with UTI + fever is presumed to have upper tract involvement → requires parenteral antibiotics initially (ceftriaxone IM/IV or aminoglycoside per IAP), with oral step-down guided by culture. Cefaclor is not adequate for pyelonephritis.
  • ⛔ Complicated UTI (structural abnormality, obstruction, renal abscess)
  • ⛔ ESBL-producing organism — cefaclor will be ineffective
  • ⛔ Empirical UTI treatment without culture — ⚠️ In India, ESBL-producing E. coli prevalence in paediatric urine isolates is high (40–70% in many centres — ICMR AMR data). Empirical cephalosporin use for paediatric UTI without culture is strongly discouraged.
• Preferred alternatives in India:
• • Uncomplicated cystitis (afebrile, >2 years): Nitrofurantoin (if ≥1 month age, afebrile, lower UTI only), cotrimoxazole, or amoxicillin-clavulanate — culture-directed
  • Febrile UTI / suspected pyelonephritis: Ceftriaxone IM/IV, amikacin/gentamicin IV (IAP/MoHFW) initially, then oral step-down
• Mandatory baseline investigations: Urine culture — clean-catch midstream (toilet-trained), catheter specimen or suprapubic aspirate (infants/non-toilet-trained) — MANDATORY before starting antibiotics. Renal ultrasound (recommended). Serum creatinine (recommended if systemic illness).
• Post-treatment work-up: Repeat urine culture to confirm eradication (especially <5 years). Renal ultrasound for all first febrile UTIs in children <2 years and in older children with recurrent UTI or atypical features. MCUG/VCUG (recommended in children <2 years after first febrile UTI to rule out vesicoureteral reflux — per IAP protocol).
• Duration: 7–10 days for lower UTI; 10–14 days for pyelonephritis (but cefaclor is rarely appropriate for pyelonephritis).
• Time to expected clinical response: Dysuria/frequency improve within 24–48 hours. Fever (if present) resolves within 48–72 hours.
• Treatment failure criteria: Persistent symptoms at 48–72 hours → obtain/review urine culture, reassess. May need switch to parenteral therapy or broader-spectrum agent.
• Specialist initiation: Paediatric Nephrology/Urology referral for: first febrile UTI in child <2 years, recurrent UTI, abnormal renal ultrasound, suspected VUR, structural abnormalities.
• Indian guideline source: IAP Consensus Guidelines on UTI in Children (2011, updated practice); ICMR AMR surveillance; MoHFW operational guidelines.
• Key safety warning: ⚠️ Never treat paediatric UTI empirically with cephalosporins in India without sending a urine culture. High ESBL prevalence makes empirical cephalosporin therapy unreliable.

---

4. Skin and Soft Tissue Infections — Paediatric (Uncomplicated)

• When to prefer cefaclor: Alternative when cephalexin (preferred first-generation for Gram-positive skin infections) or amoxicillin-clavulanate is not available or tolerated. Reasonable for non-purulent cellulitis and streptococcal skin infections.
• When NOT to use:
• • ⛔ Purulent skin infections (abscess, furuncle, carbuncle): Frequently MRSA in Indian practice. Cefaclor has NO MRSA activity. Incision and drainage is the primary intervention; if systemic antibiotics needed, use cotrimoxazole, clindamycin, or doxycycline (≥8 years only for doxycycline).
  • ⛔ Animal or human bite wounds: Require anaerobic + Pasteurella/Eikenella coverage → amoxicillin-clavulanate is the drug of choice. Cefaclor is inadequate.
  • ⛔ Deep-seated or necrotising infections (necrotising fasciitis, osteomyelitis, septic arthritis) — require parenteral antibiotics and surgical consultation.
• For impetigo specifically: Localised impetigo (<5 lesions, small area) → topical mupirocin 2% or fusidic acid 2% is first-line (IAP/IADVL). Systemic antibiotics (including cefaclor) only for extensive, spreading, or bullous impetigo, or when topical therapy has failed. This follows antimicrobial stewardship principles.
• Preferred alternatives in India: Cephalexin (first-generation — narrower spectrum, preferred per stewardship); amoxicillin-clavulanate; cloxacillin/flucloxacillin (if MSSA confirmed).
• Time to expected clinical response: 48–72 hours. Mark borders of cellulitis with a skin marker for objective tracking.
• Key safety warning: ⚠️ Community-acquired MRSA (CA-MRSA) prevalence in Indian paediatric SSTI is increasing. Do not assume staphylococcal infection is MSSA without culture support in areas of high MRSA prevalence.
• Specialist initiation: Not required for uncomplicated SSTI. Surgical referral for abscess drainage. Infectious Disease referral for deep-seated or non-resolving infections.
• Indian guideline source: IAP Infectious Disease Chapter guidelines; IADVL guidelines for paediatric skin infections.

---

Secondary Indications — Paediatric (Off-Label)

---

1. Low-Dose Prophylaxis for Recurrent UTI in Children with Vesicoureteral Reflux (VUR)

• Status: OFF-LABEL but accepted standard practice in India (IAP Paediatric Nephrology guidelines support antibiotic prophylaxis in VUR grades III–V with recurrent febrile UTI or renal scarring)
• Dose: 10 mg/kg/dose once daily at bedtime (approximately one-third to one-half of the therapeutic daily dose)
• Maximum dose: Max 250 mg per dose; Max 250 mg per day (prophylactic dosing)
• Duration: 6–12 months minimum; may continue until VUR resolves spontaneously or is surgically corrected — duration guided by Paediatric Nephrologist/Urologist
• Specialist only: ⚠️ Yes — Paediatric Nephrology or Urology supervision mandatory. Decision to start and continue prophylaxis must be based on VUR grade, breakthrough UTI frequency, renal scarring status, and ongoing imaging follow-up.
• Clearly marked: OFF-LABEL but accepted standard practice in India
• Evidence basis: Prophylactic antibiotics for VUR evaluated in several paediatric RCTs (RIVUR trial — used cotrimoxazole; Swedish Reflux Trial). Overall evidence supports modest benefit in reducing febrile UTI recurrence, particularly in high-grade VUR. Cefaclor is one of several agents used; nitrofurantoin and cotrimoxazole are more commonly recommended and have stronger direct evidence.
• Level of evidence quality:Moderate — Paediatric RCTs exist for the principle of antibiotic prophylaxis in VUR. Data specific to cefaclor (vs nitrofurantoin or cotrimoxazole) is limited — evidence is extrapolated from the class and from clinical practice.
• Preferred alternatives for UTI prophylaxis in children:
• • Nitrofurantoin 1–2 mg/kg at bedtime (most commonly recommended in India and internationally)
  • Cotrimoxazole 1–2 mg/kg (TMP component) at bedtime (widely used in Indian paediatric practice)
  • Cephalexin 10 mg/kg at bedtime (preferred cephalosporin for this purpose — first-generation, narrower spectrum)
• Clinical note: ⚠️ Long-term cephalosporin use for UTI prophylaxis may promote ESBL-producing organism selection. Prefer nitrofurantoin or cotrimoxazole when possible. Current paediatric nephrology trend (including in Indian practice) is toward more selective use of antibiotic prophylaxis — not all children with VUR require prophylaxis. IAP and Indian paediatric nephrology consensus increasingly recommend prophylaxis mainly for high-grade VUR (Grade III–V) with recurrent febrile UTI or renal scarring. Periodic urine cultures (every 3–6 months) and annual renal ultrasound recommended during prophylaxis.
• Age restriction: May be used from 1 month of age under specialist guidance.
• Indian guideline source: IAP Standard Treatment Guidelines — Paediatric Nephrology; IAP Consensus Statement on UTI Prophylaxis.

---

---

---

RENAL ADJUSTMENT

ℹ️ eGFR Formula Specification: The dosing adjustments below are primarily based on creatinine clearance (CrCl) estimated by the Cockcroft-Gault equation, consistent with the original pharmacokinetic studies for cefaclor. CKD-EPI eGFR values may differ, especially in elderly patients, extreme body weights, and advanced CKD. In elderly patients (≥60 years), Cockcroft-Gault CrCl may yield lower values than CKD-EPI eGFR due to the effect of body weight and age — this could lead to more conservative (lower) dosing if Cockcroft-Gault is used. Either estimate is acceptable; the key is to assess renal function before prescribing in at-risk patients.

ℹ️ For paediatric patients: Use the Schwartz formula (bedside Schwartz equation using serum creatinine) for estimating GFR.

ℹ️ Key Pharmacokinetic Rationale: Cefaclor is primarily excreted by the kidneys (60–85% unchanged). Half-life is prolonged from ~0.6–0.9 hours (normal renal function) to ~2.3–2.8 hours (CrCl <10 mL/min). However, due to the relatively wide therapeutic index of cefaclor, dose adjustments are generally required only in moderate-to-severe renal impairment.

---

Adult Renal Dosing Adjustment Table

---

Paediatric Renal Dosing Adjustment

---

CD/SR Tablets in Renal Impairment — Special Note

---

Augmented Renal Clearance (ARC)

ℹ️ ARC (CrCl >130 mL/min) in young, non-elderly ICU patients (sepsis, trauma, burns) could theoretically lead to enhanced cefaclor elimination and subtherapeutic levels. However, for cefaclor specifically, ARC is unlikely to be clinically significant because:

• 1. Cefaclor is rarely the antibiotic of choice in ICU settings where ARC occurs
  2. The clinical scenario of a patient sick enough to have ARC would typically prompt use of a parenteral antibiotic rather than dose-escalation of oral cefaclor

No specific ARC dose increase recommendation for cefaclor. If cefaclor is used in an exceptional circumstance in a patient with suspected ARC, use the maximum recommended dose (500 mg TDS for IR) and reassess whether a parenteral antibiotic would be more appropriate.

---

Source of Recommendations

---

---

HEPATIC ADJUSTMENT

Formal Child-Pugh-Based Data

ℹ️ No formal Child-Pugh-based dosing studies exist for cefaclor. The clinical guidance below is based on pharmacokinetic principles.

---

Pharmacokinetic Rationale

---

Clinical Guidance by Severity

---

Summary Statement

✅ Cefaclor does NOT require dose adjustment for hepatic impairment alone. Hepatic metabolism is a minor elimination pathway, protein binding is low, and no active metabolites accumulate. The main clinical concern in patients with liver disease is concurrent renal impairment — dose-adjust for renal function, not liver function.

---

Concurrent Hepatotoxin Note

ℹ️ Cefaclor is not significantly hepatotoxic. Rare cases of transient transaminase elevation have been reported (<0.1%) but clinically significant hepatotoxicity is very uncommon.

---

CONTRAINDICATIONS

---

1. Known Hypersensitivity to Cefaclor

---

2. Known Anaphylaxis to Any Cephalosporin

---

3. Known Anaphylaxis to Any Penicillin (with Important Nuance)

---

Allergy Cross-Reactivity — Detailed Guidance

---

4. Established Cephalosporin-Induced Immune Haemolytic Anaemia

---

CAUTIONS

⚠️ High-Priority Cautions

---

• Observe for ≥30 minutes after the first dose in a healthcare setting if feasible
• Counsel the patient/caregiver on signs of allergic reaction (rash, swelling, breathing difficulty)
• Have emergency medications available (adrenaline, antihistamines, corticosteroids)
• If doubt exists about the nature of the previous penicillin reaction, consider allergist referral for skin testing before prescribing any beta-lactam — though allergist access is limited in most Indian settings

---

• Assess renal function (serum creatinine, eGFR) before prescribing in patients with known or suspected renal disease, elderly patients, and patients on concurrent nephrotoxic drugs
• Dose adjustment required for eGFR <30 mL/min — see Renal Adjustment (Part 3)
• Monitor for signs of drug accumulation: increased GI side effects, headache, dizziness
• Use IR formulation (not CD/SR) for CrCl <30 mL/min to allow precise dose adjustment

---

• Counsel about signs of CDI: watery diarrhoea (≥3 loose stools/day), abdominal cramping, fever, blood/mucus in stool
• If CDI suspected → discontinue cefaclor immediately, send stool for C. difficile toxin assay, and initiate specific CDI treatment (oral vancomycin or fidaxomicin per Indian guidelines)
• Do not use antidiarrhoeal agents (loperamide) if CDI suspected — they can worsen toxin retention

---

• Check INR at baseline and within 3–5 days of starting cefaclor in patients on stable warfarin therapy
• Be alert for signs of over-anticoagulation (easy bruising, petechiae, gum bleeding, blood in urine/stool)
• Adjust warfarin dose if INR rises above therapeutic range
• The interaction is usually modest and self-limiting (resolves after the antibiotic course ends)

---

• In patients with epilepsy: use standard doses, ensure renal function is adequate (dose-adjust in renal impairment to prevent accumulation)
• If new-onset seizure occurs during cefaclor therapy in a renally impaired patient → consider drug accumulation as a contributing factor

---

Standard Cautions

---

• This is clinically relevant in India where Benedict’s test is still used in some PHCs and smaller laboratories for urine glucose screening
• Advise diabetic patients and laboratory staff that a positive urine glucose test during cefaclor therapy should be confirmed with a glucose oxidase method or blood glucose measurement
• Blood glucose monitoring (glucometer) is not affected by cefaclor

---

• Clinically relevant if blood cross-matching is needed (e.g., pre-surgical, pre-transfusion) — inform the blood bank that the patient is on cefaclor
• Also relevant if investigating for haemolytic anaemia — a positive Coombs test in a patient on cefaclor should not automatically be attributed to autoimmune haemolytic anaemia without further evaluation
• True immune haemolytic anaemia from cefaclor is very rare (see Contraindications above and Serious Adverse Effects below)

---

• Risk of superinfection (oral/vaginal candidiasis) increases with duration
• Consider periodic CBC if course exceeds 14 days — rare cases of transient eosinophilia, neutropenia, or thrombocytopenia reported with prolonged cephalosporin use
• Monitor LFTs if course is prolonged — rare transient transaminase elevation reported

---

• Monitor renal function if cefaclor is combined with nephrotoxic drugs, especially in elderly patients or those with baseline renal impairment
• In practice, this caution is rarely clinically significant for oral cefaclor

---

• Check the specific brand’s excipient list before prescribing to patients with phenylketonuria
• If aspartame is present, use an aspartame-free brand or the capsule formulation

---

---

PREGNANCY

Overall Safety Statement

---

Teratogenicity Window

---

Trimester-Specific Considerations

---

Preferred Alternatives in Indian Obstetric Practice

---

Monitoring During Use in Pregnancy

• Mother: Standard infection response monitoring (temperature, symptom resolution). Standard antenatal monitoring. No additional pregnancy-specific drug monitoring required for cefaclor.
• Foetus: No specific foetal monitoring required attributable to cefaclor use. Continue standard antenatal surveillance (growth scans, foetal movements as per routine).
• Neonatal observation: No specific neonatal observation required post-delivery for maternal cefaclor use. If cefaclor was used near delivery, observe for minor GI disturbance in neonate (loose stools) — rarely clinically significant.

---

Pre-Conception Counselling

Contraception During Use

---

Pregnancy Prevention Programme / Registry

---

Fertility Effects

---

---

LACTATION

Compatibility with Breastfeeding

---

Preferred Alternatives (If Cefaclor is Avoided)

• Amoxicillin — compatible, widely used, NLEM-listed
• Cephalexin — compatible, widely used
• Amoxicillin-clavulanate — compatible

---

Monitoring in Breastfed Infant

---

Timing Advice

---

Effect on Milk Production

---

Temporary Incompatibility Guidance

---

---

ELDERLY

Definition

---

Recommended Starting Dose

---

Titration

---

Extra Risks Specific to Elderly

---

Beers Criteria / STOPP-START Relevance

---

Monitoring Frequency Adjustments in Elderly

• Renal function: Check eGFR/serum creatinine before starting and consider rechecking if the course extends beyond 7 days or if diarrhoea/dehydration occurs.
• INR: If on warfarin — check within 3–5 days of starting cefaclor.
• Clinical response: Standard infection response monitoring (temperature, symptoms) — elderly may have blunted fever response; lack of fever improvement may not be evident even with clinical response.

---

Common Clinical Scenarios in Elderly Indian Patients

---

Anticholinergic Burden

---

Deprescribing Guidance

---

---

MAJOR DRUG INTERACTIONS

---

Food-Drug Interactions (Major)

---

Herbal / Traditional Medicine Interactions (Major)

---

---

MODERATE DRUG INTERACTIONS

---

Herbal / Traditional Medicine Interactions (Moderate)

---

Laboratory Test Interference (Classified as Moderate Interaction with Diagnostics)

---

---

COMMON ADVERSE EFFECTS

---

Very Common (≥10%)

---

Common (1–10%)

---

Dose-Response Threshold Note

• GI adverse effects (diarrhoea, nausea) are clearly dose-dependent — significantly more common at 500 mg TDS (high dose) than at 250 mg TDS (standard dose).
• Hypersensitivity reactions (rash, urticaria) are NOT dose-dependent — they are idiosyncratic and can occur at any dose.
• SSLR (see Serious ADRs) is course-dependent — risk increases with repeated courses, not with higher single doses.

---

---

SERIOUS ADVERSE EFFECTS

⚠️ PvPI Reporting: All serious adverse effects listed below must be reported to the nearest ADR Monitoring Centre under PvPI (Pharmacovigilance Programme of India) or via the ADR reporting form on the CDSCO website (https://cdsco.gov.in). Reporting suspected ADRs is a professional responsibility of every prescriber.

---

1. Serum Sickness-Like Reaction (SSLR) — Cefaclor-Specific

---

2. Anaphylaxis / Severe Immediate Hypersensitivity

---

3. Clostridioides difficile-Associated Diarrhoea (CDAD) / Pseudomembranous Colitis

---

4. Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN)

---

5. Drug-Induced Immune Haemolytic Anaemia

---

6. Hepatotoxicity

---

7. Blood Dyscrasias

---

8. Acute Interstitial Nephritis (AIN)

---

Summary: Early Warning Signs to Educate Patients/Caregivers About

---

MONITORING REQUIREMENTS

---

Baseline (Before Starting Therapy)

---

After Initiation / Dose Change

---

Long-Term / Maintenance Monitoring

---

Therapeutic Drug Monitoring (TDM)

---

When to Stop Monitoring

• Standard acute infection courses (5–14 days): Monitoring can be stopped at the end of the antibiotic course if clinical response was adequate. No follow-up blood tests needed in uncomplicated cases.
• UTI prophylaxis: Monitoring continues throughout the prophylaxis period and for 3–6 months after stopping prophylaxis (to confirm no breakthrough UTI).
• Post-SSLR surveillance: If SSLR occurred, document in permanent records. No long-term monitoring needed after SSLR resolution — the key action is to never re-expose to cefaclor.

---

---

PATIENT COUNSELLING

---

What This Medicine Is For

---

How to Take It

• ”Swallow the capsule whole with a full glass of water.“
• ”You can take it with or without food. Taking it with food may reduce stomach upset.“
• ”Take it three times a day — morning, afternoon, and night — at roughly equal intervals (every 8 hours). For example: 7 AM – 3 PM – 11 PM, or 8 AM – 2 PM – 8 PM.“
• ”Do not open the capsule or mix the powder with food.“

• ”Swallow the tablet whole — do NOT crush, break, or chew it.“
• ”⚠️ You must take it with food — preferably during or just after a meal.“
• ”Take it twice a day — morning and evening (every 12 hours).“

• ”Shake the bottle well before every dose.“
• ”Use the measuring cup or syringe provided — do not use a household teaspoon (it gives the wrong amount).“
• ”You can mix the medicine with a small amount of cold milk or juice just before giving it — but give it immediately; do not store the mixture.“
• ”⚠️ Do not mix with hot drinks.“

---

What to Do If You Miss a Dose

• ”If you remember within 3 hours of the missed dose → take it right away, then continue your regular schedule.“
• ”If it has been more than 3 hours → skip the missed dose and take the next dose at the regular time.“
• ”Never take a double dose to make up for a missed one.“

• ”If you remember within 6 hours → take it with food right away.“
• ”If it has been more than 6 hours → skip the missed dose and take the next dose at the regular time with food.“
• ”Never take a double dose.“

---

Common Side Effects to Expect

• ”Loose stools or mild diarrhoea — this is the most common side effect. It usually gets better on its own. Drink plenty of water and ORS (oral rehydration solution) if stools are very loose.“
• ”Mild stomach upset, nausea, or stomach cramps — taking the medicine with food may help.“
• ”Mild rash or itching — this may happen in some people. If it is mild and not spreading, you may continue the medicine, but tell your doctor.“

---

Warning Signs — See Your Doctor Immediately

• ”Rash with joint pain and fever — especially if it appears 1–3 weeks after starting the medicine (this could be a reaction called serum sickness-like reaction)“
• ”Difficulty breathing, swelling of the face, lips, or throat, or a widespread itchy rash — these are signs of a serious allergic reaction (this is rare but requires emergency treatment)“
• ”Very watery diarrhoea (more than 3 times a day), blood or mucus in stool, or severe stomach pain — this may be a serious bowel infection caused by the antibiotic“
• ”Blisters on the skin, painful sores in the mouth, or red/painful eyes — these are signs of a very rare but serious skin reaction“
• ”Yellowing of the skin or eyes, very dark urine, or very pale stools — these may be signs of a liver problem“
• ”Unusual tiredness, paleness, or a very fast heartbeat — these may be signs of a blood problem“

---

Things to Avoid

• ”Alcohol: No specific interaction with cefaclor. Moderate alcohol consumption during the course is unlikely to be harmful, but alcohol may worsen nausea and stomach upset. It is best to avoid or limit alcohol while you are unwell.“
• ”Antacids: If you are taking antacids (like Gelusil, Digene), take them at least 2 hours apart from the CD/SR tablet. No precaution needed with the capsule or liquid forms.“
• ”Do not share this medicine with anyone else, even if they have similar symptoms.“
• ”Do not use leftover antibiotics from a previous course.“

---

Storage

• ”Keep in a cool, dry place away from sunlight. Room temperature (below 30°C) is fine.“
• ”Keep out of reach of children.“

• ”⚠️ Store in the refrigerator (2–8°C) after mixing. The medicine lasts 14 days in the fridge.“
• ”If you do not have a refrigerator: keep in the coolest part of your home (away from sunlight and heat) and use within 7 days.“
• ”In Indian summer temperatures (>35°C), refrigeration is strongly recommended to maintain the medicine’s quality.“
• ”Throw away any leftover liquid medicine after 14 days — even if some is left in the bottle.“

---

Duration

• ”This medicine is for a short course — usually 5 to 14 days depending on your infection.“
• ”Your doctor will tell you exactly how many days to take it.“
• ”⚠️ Complete the full course. Do not stop early even if you feel better.“
• ”This is especially important for throat infections — your doctor may tell you to take it for 10 full days to prevent a heart problem called rheumatic fever.“

---

Follow-Up

• ”Come back to your doctor if your symptoms have not improved within 3 days of starting the medicine.“
• ”If your doctor asked for a urine test or blood test, make sure to get it done as advised.“
• ”If you are taking blood thinners (warfarin/Acitrom), your doctor may ask for an INR blood test within a few days of starting this antibiotic.“

---

Common Patient Questions Addressed

---

Caregiver / Family Counselling

• How to measure the correct dose using the measuring cup/syringe (demonstrate if possible)
• How to store the liquid medicine (refrigerate after mixing; discard after 14 days)
• Shake the bottle well before every dose
• Watch for warning signs: rash with joint pain, difficulty breathing, severe diarrhoea, blisters on skin — and when to bring the patient back
• Complete the full course — do not stop early, even if the child/patient seems better
• Keep the medicine out of reach of other children in the household

---

India-Specific Adherence Support

---

---

BRANDS AVAILABLE IN INDIA

---

Jan Aushadhi / PMBJP Brands

---

Major / Commonly Available Private Brands

• Keflor / Keflor CD (Sun Pharma, formerly Ranbaxy) is the most widely recognised cefaclor brand in Indian practice.
• CD/SR (modified-release) tablets have limited availability — primarily stocked in metro/urban pharmacies. Rural and PHC pharmacies are unlikely to carry this formulation. If prescribing CD/SR, confirm local availability before writing the prescription.
• Oral drops formulation has very limited brand availability in India. Confirm brand-specific concentration before prescribing.
• FDC brands: No cefaclor-containing FDCs are in common clinical use in India.

CDSCO Regulatory Alerts

---

---

PRICE RANGE (INR)

ℹ️ Prices as of June 2025. Verify current prices on NPPA / 1mg / PharmEasy / Jan Aushadhi price lists as prices may change. Prices listed are approximate MRP (Maximum Retail Price) per unit or per pack for commonly available brands.

---

Per-Unit Price Estimates

---

Estimated Monthly / Per-Course Cost

---

NPPA / NLEM / Government Supply Notes

---

Comparative Cost Context

---

---

CLINICAL PEARLS

• Skin infections / SSTI: Cephalexin is preferred (better MSSA activity, narrower spectrum, cheaper).
• AOM / Sinusitis where H. influenzae or M. catarrhalis is suspected: Cefaclor has an advantage over cephalexin.
• For most infections where a cephalosporin is indicated, amoxicillin-clavulanate provides broader and more reliable coverage than either.

---

VERSION

---

---

REFERENCES

---

CDSCO Product Insert

1. CDSCO Product Insert — Keflor (cefaclor), Sun Pharmaceutical Industries Ltd (formerly Ranbaxy Laboratories). Most recent available revision.
2. CDSCO Product Insert — Keflor CD (cefaclor monohydrate modified-release tablets), Sun Pharmaceutical Industries Ltd. Most recent available revision.

---

Indian Pharmacopoeia / National Formulary

1. Indian Pharmacopoeia Commission. Indian Pharmacopoeia 2022. Monograph: Cefaclor Capsules; Cefaclor for Oral Suspension. Ghaziabad: IPC.

---

NLEM India

1. Ministry of Health and Family Welfare, Government of India. National List of Essential Medicines (NLEM) India 2022. [Cefaclor is not included — referenced to confirm non-inclusion and to identify NLEM-listed alternatives: amoxicillin, amoxicillin-clavulanate, cephalexin, cefixime, nitrofurantoin.]

---

Indian Guidelines

1. ICMR (Indian Council of Medical Research). Treatment Guidelines for Antimicrobial Use in Common Syndromes. 2nd Edition, 2019. New Delhi: ICMR. [Chapters on: URTI, LRTI/CAP, UTI, SSTI — antibiotic selection and stewardship principles.]
2. ICMR. Annual Report — Antimicrobial Resistance Research and Surveillance Network (AMR). Latest available year. [Referenced for Indian E. coli/Klebsiella cephalosporin resistance rates, ESBL prevalence data, and community vs hospital resistance patterns.]
3. Indian Academy of Pediatrics (IAP). IAP Guidelines for Management of Acute Otitis Media. Indian Pediatrics, published guidelines. [Referenced for AOM diagnosis, antibiotic selection, watchful waiting criteria, and treatment failure management in children.]
4. Indian Academy of Pediatrics (IAP). IAP Guidelines for Management of Community-Acquired Pneumonia in Children. Indian Pediatrics, published guidelines. [Referenced for CAP severity assessment, antibiotic selection, duration, and referral criteria.]
5. Indian Academy of Pediatrics (IAP). IAP Revised Guidelines for Diagnosis and Management of Rheumatic Fever. Indian Pediatrics, 2008 (with updated practice endorsed subsequently). [Referenced for GAS pharyngitis treatment duration, benzathine penicillin G dosing, and rheumatic fever prevention.]
6. Indian Academy of Pediatrics (IAP). IAP Consensus Guidelines on UTI in Children. Indian Pediatrics, 2011 (with updated practice). [Referenced for paediatric UTI diagnosis, urine culture requirements, imaging workup, VUR management, and antibiotic prophylaxis.]
7. Indian Academy of Pediatrics (IAP). IAP Standard Treatment Guidelines — Paediatric Nephrology Section. [Referenced for UTI prophylaxis in VUR, prophylactic antibiotic selection, and duration of prophylaxis.]
8. API (Association of Physicians of India). API Textbook of Medicine. 11th Edition (latest available). Relevant chapters: Streptococcal Infections; Urinary Tract Infections; Community-Acquired Pneumonia; Skin and Soft Tissue Infections; Antimicrobial Therapy Principles. [Referenced for Indian clinical practice patterns, antibiotic selection recommendations, and disease management.]
9. Indian Association of Dermatologists, Venereologists and Leprologists (IADVL). IADVL Guidelines for Bacterial Skin Infections. [Referenced for impetigo and SSTI management, topical vs systemic antibiotic selection.]
10. National Neonatology Forum (NNF) of India / IAP. NNF Guidelines on Neonatal Sepsis Management. [Referenced for neonatal antibiotic selection — to confirm cefaclor is not part of neonatal sepsis protocols.]
11. Indian Chest Society / National College of Chest Physicians (NCCP). Indian Guidelines for Management of COPD. [Referenced for AECB antibiotic selection and Anthonisen criteria application in Indian practice.]

---

International Textbooks (Used for Pharmacology Depth)

1. Brunton LL, Hilal-Dandan R, Knollmann BC (eds). Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th Edition. McGraw-Hill. Chapter on Beta-Lactam Antibiotics: Cephalosporins. [Referenced for: cefaclor pharmacokinetics (bioavailability, Tmax, protein binding, Vd, half-life, renal excretion, dialysability), mechanism of action (beta-lactam ring, PBP binding, time-dependent killing), spectrum of activity, cross-reactivity pharmacology (R1 side chain structure), PEPT1 transporter absorption, OAT-mediated renal secretion, probenecid interaction mechanism, SSLR metabolite (delta-3 intermediate) biochemistry.]
2. Jameson JL, Fauci AS, Kasper DL, et al. (eds). Harrison’s Principles of Internal Medicine. 21st Edition. McGraw-Hill. Relevant chapters: Treatment of Bacterial Infections; Pneumonia; Urinary Tract Infections; Pharyngitis; Otitis Media. [Referenced for general infectious disease management principles, antibiotic selection frameworks, and drug allergy cross-reactivity guidance.]

---

WHO / International Guidelines (Supportive Only)

1. World Health Organization (WHO). Pocket Book of Hospital Care for Children. 2nd Edition, 2013 (updated 2022). [Referenced as supportive reference for paediatric pneumonia severity classification, respiratory rate thresholds, and danger signs — adapted for Indian practice per IAP/IMNCI.]
2. World Health Organization (WHO). WHO Model List of Essential Medicines for Children. 9th List, 2023. [Referenced to confirm cefaclor is not included in WHO EML for Children.]

---

Specific Evidence for Off-Label Indications

1. RIVUR Trial Investigators. Craig JC, et al. Antibiotic prophylaxis and recurrent urinary tract infection in children. N Engl J Med. 2014;370(25):2367–2376. [Referenced for evidence basis of antibiotic prophylaxis in paediatric VUR — used cotrimoxazole, not cefaclor specifically, but supports the general principle cited for the off-label VUR prophylaxis indication.]
2. Brandström P, et al (Swedish Reflux Trial). The Swedish Reflux Trial in Children: IV. Renal Damage. J Urol. 2010;184(1):292–297. [Referenced alongside RIVUR for the VUR prophylaxis evidence basis.]

---

Pharmacovigilance

1. Pharmacovigilance Programme of India (PvPI). Central Drugs Standard Control Organisation (CDSCO). [Referenced for ADR reporting requirements and PvPI reporting pathway for serious adverse effects.]

---

Pricing and Availability

1. National Pharmaceutical Pricing Authority (NPPA). Drug Price Control Orders (DPCO) and ceiling price lists. Current edition. [Referenced to confirm cefaclor is not under NPPA price control.]
2. Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP). Jan Aushadhi Product List. Current edition (janaushadhi.gov.in). [Referenced to confirm cefaclor availability status in Jan Aushadhi stores.]
3. Retail pharmacy price surveys and online pharmacy platforms (1mg.com, PharmEasy.in). [Referenced for approximate MRP data for cefaclor brands, accessed June 2025.]

---